Physician profile
Amanda Hardy
NPI 1174051643
$3,467.96
in general payments reported to CMS, 2019-2025
36 companies · $507 in 2025
The $507 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $598 · 2023: $773 · 2024: $774 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.79 | 2021-2025 | |
| Lilly USA, LLC | $436.18 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $435.99 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $332.18 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $280.94 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $274.74 | 2021-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $124.69 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $115.78 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.35 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $90.57 | 2022-2023 | |
| Radius Health, INC. | $66.50 | 2023-2024 | Tymlos |
| Pfizer INC. | $65.52 | 2021 | |
| Mylan Specialty L.P. | $51.47 | 2023-2024 | Yupelri |
| Scilex Pharmaceuticals INC. | $43.97 | 2022 | |
| Viatris Specialty LLC | $40.58 | 2025 | Yupelri |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.